Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive function after liver transplantation comparing Tacrolimus formulations
2024-513963-22-00Phase 4Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Oct 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in immunocompromise (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Change in subjective impression of quality of life concerning attention/concentration and memory. Started Oct 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2024-513963-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513963-22-00.